Clinical trial · Observational
Adaptation of the PROFFIT Instrument Into Turkish: A Validity and Reliability Study
Adaptation of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) Instrument Into Turkish: A Validity and Reliability Study
NCT07088978CI-TRIAL-00096195not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the Turkish validity and reliability of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) developed in Italy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- Validity Assessment-Language and Content Validity
- timeFrame
- Through study completion, an average of 12 months
- description
- Language and Content Validity: To assess the relevance and appropriateness of the translated items, a panel of at least six experts in oncology, psychology, and instrument development will evaluate each item.
- measure
- Validity Assessment-Content Validity Index (CVI)
- timeFrame
- Through study completion, an average of 12 months
- description
- Content Validity Index (CVI) will be calculated based on expert ratings to determine the proportion of items deemed relevant.
- measure
- Validity Assessment-Content Validity Ratio (CVR)
- timeFrame
- Through study completion, an average of 12 months
- description
- Content Validity Ratio (CVR) will be used to assess whether each item is essential for measuring the construct.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Individuals diagnosed with solid cancer or hematologic malignancy, either histologically or cytologically, and aware of their diagnosis, * Those who have received cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, radiotherapy, or a combination of these treatments) within the last three months, * Individuals over the age of 18, * Those without a diagnosed psychiatric illness (such as depression, panic attacks, schizophrenia, etc.), * Individuals without auditory or cognitive impairments, * Turkish-speaking and literate volunteers. Exclusion Criteria: * Individuals who fill out the data collection forms incompletely or wish to withdraw from the study.
References
Publications (0)
Data not yet available
No reference posted for this study.